Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 10/2006

01-10-2006 | Letter

Primary Solitary Extragastrointestinal Stromal Tumor of the Greater Omentum Coexisting with Ulcerative Colitis

Authors: Andreas M. Kaiser, Jung-Cheng Kang, Andre R. Tolazzi, Andy E. Sherrod, Robert W. Beart Jr

Published in: Digestive Diseases and Sciences | Issue 10/2006

Login to get access

Excerpt

To the Editor …
Literature
1.
Kim CJ, Day S, Yeh KA (2001) Gastrointestinal stromal tumors: analysis of clinical and pathologic factors. Am Surg 67:135–137PubMed
2.
Miettinen M, Majidi M, Lasota J (2002) Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 38(Suppl 5):S39–S51PubMedCrossRef
3.
Miettinen M, Monihan JM, Sarlomo-Rikala M, et al (1999) Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Path 23:1109–1118PubMedCrossRef
4.
DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58PubMedCrossRef
5.
Takahashi T, Kuwao S, Yanagihara M, Kakita A (1998) A primary solitary tumor of the lesser omentum with immunohistochemical features of gastrointestinal stromal tumors. Am J Gastroenterol 93:2269–2273PubMedCrossRef
6.
Kaiser AM, Beart RW Jr (2001) Surgical management of ulcerative colitis. Swiss Med Wkly 131:323–337PubMed
7.
Chandrasoma P. Gastrointestinal pathology. Stamford, CT, Appleton & Lange
8.
Fletcher CD, Berman JJ, Corless C, et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 10:81–89PubMed
9.
Koh JS, Trent J, Chen L, et al (2004) Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate. Histol Histopathol 19:565–574PubMed
10.
Koay MH, Goh YW, Iacopetta B, et al (2005) Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases. Pathology 37:22–31PubMedCrossRef
11.
Corless CL (2004) Assessing the prognosis of gastrointestinal stromal tumors: a growing role for molecular testing. Am J Clin Pathol 122:11–13PubMedCrossRef
12.
Kim TW, Lee H, Kang YK, et al (2004) Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 10:3076–3081PubMedCrossRef
13.
Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M (1998) CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Modern Pathol 11:728–734
14.
Medeiros F, Corless CL, Duensing A, et al (2004) KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28:889–894PubMedCrossRef
15.
Eisenberg BL, Judson I (2004) Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 11:465–475PubMedCrossRef
16.
Besana-Ciani I, Boni L, Dionigi G, Benevento A, Dionigi R (2003) Outcome and long term results of surgical resection for gastrointestinal stromal tumors (GIST). Scand J Surg 92:195–199PubMed
17.
Demetri GD, von Mehren M, Blanke CD, et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRef
18.
Verweij J, Casali PG, Zalcberg J, et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134PubMedCrossRef
19.
Grieco A, Cavallaro A, Potenza AE, et al (2002) Gastrointestinal stromal tumor (GIST) and ulcerative colitis. J Exp Clin Cancer Res 21:617–620PubMed
Metadata
Title
Primary Solitary Extragastrointestinal Stromal Tumor of the Greater Omentum Coexisting with Ulcerative Colitis
Authors
Andreas M. Kaiser
Jung-Cheng Kang
Andre R. Tolazzi
Andy E. Sherrod
Robert W. Beart Jr
Publication date
01-10-2006
Published in
Digestive Diseases and Sciences / Issue 10/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9217-y

Other articles of this Issue 10/2006

Digestive Diseases and Sciences 10/2006 Go to the issue

Original Paper

Leptin in the Field of Hepatic Fibrosis: A Pivotal or an Incidental Player?

Case Report

Central Retinal Vein Thrombosis in a Patient with Ulcerative Colitis

Original Paper

Evaluation of α-Glutathione-S-Transferase as a Biomarker of Lamivudine Therapy for Chronic Hepatitis B

Original Paper

Helicobacter pylori Infection is Associated with a High Incidence of Intestinal Metaplasia in the Gastric Mucosa of Patients at Inner-City Hospitals in New York

Case Report

Spontaneous Rupture of a True Splenic Cyst Diagnosed by Laparoscopy

Case Report

De Novo Hepatocellular Carcinoma Occurring in a Transplanted Liver: Case Report and Review of the Literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits